Differences in expression of the cancer stem cell marker aldehyde dehydrogenase 1 among estrogen receptor-positive/human epidermal growth factor receptor type 2-negative breast cancer cases with early, late, and no recurrence

Table 5 Univariate and multivariate analyses for early recurrence in those receiving endocrine therapy and chemotherapy (early vs no recurrence)

	Early vs no recurrence in combined therapy group
	Univariate analysis	p Value	Multivariate analysis	p Value
ALDH1, ≤1 %/>1 %	4.054 (1.797–10.080)	<0.001	4.625 (1.881–12.474)	<0.001
Age, ≤50/>50 years	0.612 (0.349–1.067)	0.083	0.623 (0.330–1.164)	0.138
Tumor size, ≤20/>20 mm	2.553 (1.336–5.036)	0.004	2.130 (1.018–4.601)	0.044
Nodal metastasis negative/positive	4.357 (2.430–7.979)	<0.001	3.856 (2.026–7.519)	<0.001
Progesterone receptor staining, <20 %/≥20 %	1.035 (0.593–1.807)	0.903	Not selected
Ki-67 staining, <20 %/≥20 %	1.592 (0.858–2.983)	0.140	0.791 (0.377–1.634)	0.529
Tumor grade 1 or 2/3	2.625 (1.285–5.595)	0.007	2.098 (0.940–4.848)	0.070

ISSN: 1465-542X